These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 36607794

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Empagliflozin attenuates doxorubicin-impaired cardiac contractility by suppressing reactive oxygen species in isolated myocytes.
    Lin R, Peng X, Li Y, Wang X, Liu X, Jia X, Zhang C, Liu N, Dong J.
    Mol Cell Biochem; 2024 Aug; 479(8):2105-2118. PubMed ID: 37648958
    [Abstract] [Full Text] [Related]

  • 23. Empagliflozin ameliorates ventricular arrhythmias by inhibiting sympathetic remodeling via nerve growth factor/tyrosine kinase receptor A pathway inhibition.
    Jing Y, Ding Y, Fu H, Li T, Long T, Ye Q.
    J Cardiovasc Med (Hagerstown); 2024 Sep 01; 25(9):664-673. PubMed ID: 38949125
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. CaMKII inhibition has dual effects on spontaneous Ca2+ release and Ca2+ alternans in ventricular cardiomyocytes from mice with a gain-of-function RyR2 mutation.
    Sadredini M, Haugsten Hansen M, Frisk M, Louch WE, Lehnart SE, Sjaastad I, Stokke MK.
    Am J Physiol Heart Circ Physiol; 2021 Aug 01; 321(2):H446-H460. PubMed ID: 34270372
    [Abstract] [Full Text] [Related]

  • 26. Increased Reactive Oxygen Species-Mediated Ca2+/Calmodulin-Dependent Protein Kinase II Activation Contributes to Calcium Handling Abnormalities and Impaired Contraction in Barth Syndrome.
    Liu X, Wang S, Guo X, Li Y, Ogurlu R, Lu F, Prondzynski M, de la Serna Buzon S, Ma Q, Zhang D, Wang G, Cotton J, Guo Y, Xiao L, Milan DJ, Xu Y, Schlame M, Bezzerides VJ, Pu WT.
    Circulation; 2021 May 11; 143(19):1894-1911. PubMed ID: 33793303
    [Abstract] [Full Text] [Related]

  • 27. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.
    Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A, DeMarco VG.
    Cardiovasc Diabetol; 2017 Jan 13; 16(1):9. PubMed ID: 28086951
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. SGLT2 inhibitor-empagliflozin treatment ameliorates diabetic retinopathy manifestations and exerts protective effects associated with augmenting branched chain amino acids catabolism and transportation in db/db mice.
    Gong Q, Zhang R, Wei F, Fang J, Zhang J, Sun J, Sun Q, Wang H.
    Biomed Pharmacother; 2022 Aug 13; 152():113222. PubMed ID: 35671581
    [Abstract] [Full Text] [Related]

  • 31. Ca2+/calmodulin-dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca2+ leak in heart failure.
    Ai X, Curran JW, Shannon TR, Bers DM, Pogwizd SM.
    Circ Res; 2005 Dec 09; 97(12):1314-22. PubMed ID: 16269653
    [Abstract] [Full Text] [Related]

  • 32. Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2.
    Chen S, Wang Q, Bakker D, Hu X, Zhang L, van der Made I, Tebbens AM, Kovácsházi C, Giricz Z, Brenner GB, Ferdinandy P, Schaart G, Gemmink A, Hesselink MKC, Rivaud MR, Pieper MP, Hollmann MW, Weber NC, Balligand JL, Creemers EE, Coronel R, Zuurbier CJ.
    Basic Res Cardiol; 2024 Oct 09; 119(5):751-772. PubMed ID: 39046464
    [Abstract] [Full Text] [Related]

  • 33. Reduction of SR Ca2+ leak and arrhythmogenic cellular correlates by SMP-114, a novel CaMKII inhibitor with oral bioavailability.
    Neef S, Mann C, Zwenger A, Dybkova N, Maier LS.
    Basic Res Cardiol; 2017 Jul 09; 112(4):45. PubMed ID: 28612156
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy.
    Li N, Zhou H.
    Drug Des Devel Ther; 2020 Jul 09; 14():4775-4788. PubMed ID: 33192053
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Stabilizing cardiac ryanodine receptor prevents the development of cardiac dysfunction and lethal arrhythmia in Ca2+/calmodulin-dependent protein kinase IIδc transgenic mice.
    Sufu-Shimizu Y, Okuda S, Kato T, Nishimura S, Uchinoumi H, Oda T, Kobayashi S, Yamamoto T, Yano M.
    Biochem Biophys Res Commun; 2020 Apr 02; 524(2):431-438. PubMed ID: 32007269
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.